Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool aims to predict liver cancer return after surgery

NCT ID NCT07062380

Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing an artificial intelligence (AI) model to see if it can predict whether early-stage liver cancer will come back within two years after surgery. About 353 adults with early-stage liver cancer will have standard surgery and then be monitored with scans. Their medical data and images will be used to train and check the AI's predictions. The goal is to improve follow-up care by identifying high-risk patients earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help doctors identify patients at high risk of cancer recurrence early, allowing for closer monitoring or timely treatment adjustments.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 353 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll patients with early-stage hepatocellular carcinoma (BCLC 0-A) scheduled for curative liver resection at tertiary academic medical centers in China. Participants will be consecutively recruited from hepatobiliary surgery clinics, with preoperative MRI and postoperative pathology confirmation of HCC. The population reflects real-world clinical practice, including both surgery-only patients and those receiving neoadjuvant/adjuvant therapies per physician discretion.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years, regardless of gender. * BCLC stage 0-A, scheduled for curative liver resection. * Preoperative clinical diagnosis of hepatocellular carcinoma (HCC). * Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality. * Child-Pugh liver function score ≤7. * ECOG Performance Status (PS) 0-1. * No severe organic diseases of the heart, lungs, brain, or other vital organs. Exclusion Criteria: * Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ). * Postoperative pathology confirms non-HCC diagnosis. * Pregnant or lactating women. * History of organ transplantation. * Inability to comply with the study protocol or follow-up schedule.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatecellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatecellular carcinoma Hepatectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji Hospital

    RECRUITING

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.